Sign inJoin waitlistJoin the waitlist

Diane Prager

Associate Clinical Professor · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · ·

History

UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Hematology and Medical Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
1994–1997
Internal Medicine
Cedars-Sinai Medical Center
1988–1991
St. John's Eye Hospital
1983–1985
Johannesburg Hospital
1982–1983
UNIV OF THE WITWATERSRAND, MED SCH, JOHANNESBURG, SOUTH AFRICA
1978–1982

Research

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
JAMA · 2003 · 2,159 citations
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Journal of Clinical Oncology · 2005 · 1,174 citations
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
Journal of Clinical Oncology · 2007 · 239 citations

Shlomo Melmed
16 papers
Joseph Rosenblatt
4 papers
RH
Roy Herbst
4 papers
CB
Chandra Belani
3 papers
MK
Mark Kris
3 papers
BJ
Bruce Johnson
2 papers
David Cella
2 papers
David Johnson
2 papers
JS
Joan Schiller
2 papers
RN
Ronald Natale
2 papers
Thomas Lynch
2 papers
AL
Alan Lichtenstein
1 paper

Grants

Disordered Polypeptide Hormone Expression
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $797.2K · University of California Los Angeles
1993–1999
Insulin Action in the Cell Nucleus
National Institute of Diabetes and Digestive and Kidney Diseases · K08
Contact PI · $429.1K · Cedars-Sinai Medical Center
1991–1997

Clinical trials

CCI-779 in Treating Patients With Prostate Cancer
Study chair · Completed · Phase 2
Jonsson Comprehensive Cancer Center
2000–2004
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Study chair · Completed · Phase 1, Phase 2
Jonsson Comprehensive Cancer Center
1997–2001